First-in-Human PET Imaging and Estimated Radiation Dosimetry of l-[5- 11 C]-Glutamine in Patients with Metastatic Colorectal Cancer.

Autor:	Cohen AS; Vanderbilt Center for Molecular Probes, Vanderbilt University Medical Center, Nashville, Tennessee.; Vanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center, Nashville, Tennessee., Grudzinski J; Internal Dosimetry Consultants, LLC, Madison, Wisconsin., Smith GT; Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, Tennessee.; Section Chief, Nuclear Medicine, Tennessee Valley Healthcare System, Nashville VA Medical Center, Nashville, Tennessee., Peterson TE; Vanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center, Nashville, Tennessee.; Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, Tennessee., Whisenant JG; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee; and., Hickman TL; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee; and., Ciombor KK; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee; and., Cardin D; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee; and., Eng C; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee; and., Goff LW; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee; and., Das S; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee; and., Coffey RJ; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee; and.; Department of Cell and Developmental Biology, Vanderbilt University, Nashville, Tennessee., Berlin JD; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee; and., Manning HC; Vanderbilt Center for Molecular Probes, Vanderbilt University Medical Center, Nashville, Tennessee; hcmanning@mdanderson.org.; Vanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center, Nashville, Tennessee.; Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, Tennessee.; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee; and.
Jazyk:	angličtina
Zdroj:	Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2022 Jan; Vol. 63 (1), pp. 36-43. Date of Electronic Publication: 2021 Apr 30.
DOI:	10.2967/jnumed.120.261594
Abstrakt:	Altered metabolism is a hallmark of cancer. In addition to glucose, glutamine is an important nutrient for cellular growth and proliferation. Noninvasive imaging via PET may help facilitate precision treatment of cancer through patient selection and monitoring of treatment response. l-[5- 11 C]-glutamine ( 11 C-glutamine) is a PET tracer designed to study glutamine uptake and metabolism. The aim of this first-in-human study was to evaluate the radiologic safety and biodistribution of 11 C-glutamine for oncologic PET imaging. Methods: Nine patients with confirmed metastatic colorectal cancer underwent PET/CT imaging. Patients received 337.97 ± 44.08 MBq of 11 C-glutamine. Dynamic PET acquisitions that were centered over the abdomen or thorax were initiated simultaneously with intravenous tracer administration. After the dynamic acquisition, a whole-body PET/CT scan was acquired. Volume-of-interest analyses were performed to obtain estimates of organ-based absorbed doses of radiation. Results: 11 C-glutamine was well tolerated in all patients, with no observed safety concerns. The organs with the highest radiation exposure included the bladder, pancreas, and liver. The estimated effective dose was 4.46E-03 ± 7.67E-04 mSv/MBq. Accumulation of 11 C-glutamine was elevated and visualized in lung, brain, bone, and liver metastases, suggesting utility for cancer imaging. Conclusion: PET using 11 C-glutamine appears safe for human use and allows noninvasive visualization of metastatic colon cancer lesions in multiple organs. Further studies are needed to elucidate its potential for other cancers and for monitoring response to treatment. (© 2022 by the Society of Nuclear Medicine and Molecular Imaging.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu